Could HER2 Heterogeneity Open New Therapeutic Options in Patients with HER2-Primary Breast Cancer
Abstract
The purpose of this study is to determine if targeted imaging with a HER2 targeting PET tracer can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. An initial nine patients have completed the trial. Five patients demonstrated suspicious foci on 89Zr-trastuzumab PET/CT. Two of five patients with suspicious foci had biopsy proven HER2-positive metastases. In this early stage clinical trial, 89Zr-trastuzumab PET/CT may detect HER2-positive metastases in patients with HER2-negtive primary breast cancer. This is an initial proof-of-concept that targeted imaging may help identify patients eligible for targeted therapies. The problem of false positive results will need to be addressed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- AD1004117
Entities
People
- Gary A Ulaner
Organizations
- Sloan-Kettering Institute